Blatt has more than 29 years of drug research and development experience with a specific focus on biology of the immune system, infectious diseases, antiviral therapies, and relevant therapeutic interventions.
Until recently, he was the global head of infectious diseases and vaccines at Johnson and Johnson. He founded Alios BioPharma, which developed therapies for viral diseases, including respiratory syncytial virus and hepatitis C.
Prior to Alios, he was chief scientific officer of InterMune. He also held successive positions as vice president of research of Sirna/Ribozyme Therapeutics, vice president of product development at National Genetics Institute, and product development team leader, interferons at Amgen.
Blatt achieved a Ph.D. in public health administration from the University of La Verne and completed his MBA from California State University, Northridge.
Privately held Meissa Vaccines is developing vaccines to prevent viral respiratory infections. It is focused on the advancement of vaccines for respiratory syncytial virus and rhinovirus. The company is also developing vaccines for parainfluenza virus and human metapneumovirus.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine